Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11012502 | 0.78 | HSD17B10 (0.50) | TSHRCYP3A4HSD17B10MEN1KMT2A | |
| SCHEMBL11010962 | 0.78 | CD44 (0.34) | TP53TSHRCYP3A4MEN1KMT2A | |
| SCHEMBL10957865 | 0.78 | HAO1 (0.53) | AHRTP53HAO1TSHRCYP3A4 | |
| SCHEMBL1255135 | 0.78 | FBP1 (0.57) | AHRTP53HAO1TSHRCYP3A4 | |
| SCHEMBL5013607 | 0.76 | AHR (0.46) | AHRTP53HAO1TSHRCYP3A4 | |
| SCHEMBL24805337 | 0.74 | AHR (0.43) | AHRTP53HAO1TSHRCYP3A4 | |
| SCHEMBL1145370 | 0.74 | AHR (0.43) | AHRTP53HAO1TSHRCYP3A4 | |
| SCHEMBL11449130 | 0.72 | ALDH1A1 (0.45) | AHRTSHRCYP3A4HSD17B10CYP1B1 | |
| SCHEMBL9515929 | 0.72 | TDP1 (0.45) | AHRTP53HAO1TSHRCYP3A4 | |
| SCHEMBL9696956 | 0.70 | DAO (0.42) | AHRTP53HAO1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
| US-4698338-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1987-10-06 | — | — | US | disclosed |
| EP-0233780-A2 | O-substituted oximino cephalosporins | ELI LILLY AND COMPANY (US) | 1987-08-26 | — | — | EP | disclosed |
| US-4503052-A | OXACEPHALOSPORIN ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1985-03-05 | — | — | US | disclosed |
| EP-0034924-B1 | PROCESS FOR PREPARING 3-IODOMETHYL CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1984-07-04 | — | — | EP | disclosed |
| US-4338436-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4338439-A | BACTERICIDAL ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| EP-0011370-B1 | PROCESS FOR PREPARING 2-CHLOROSULFINYL-AZETIDINONES | ELI LILLY AND COMPANY (US) | 1982-04-28 | — | — | EP | disclosed |
| US-4319028-A | 7-(2-(Substituted benzoyl)amino)acetamido)cephalosporins | ELI LILLY AND COMPANY (US) | 1982-03-09 | — | — | US | disclosed |
| US-4289695-A | REACTION OF A PHENICILLIN WITH AN N-CHLORO HALOGENATING AGENT IN PRESENCE OF A CROSSLINKED POLYVINYLPYRIDINE | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0034924-A2 | Process for preparing 3-iodomethyl cephalosporins | ELI LILLY AND COMPANY (US) | 1981-09-02 | — | — | EP | disclosed |
| US-4266049-A | Process for 3-iodomethyl cephalosporins | ELI LILLY AND COMPANY (US) | 1981-05-05 | — | — | US | disclosed |
| EP-0011370-A1 | Process for preparing 2-chlorosulfinyl-azetidinones | ELI LILLY AND COMPANY (US) | 1980-05-28 | — | — | EP | disclosed |
| US-4159272-A | Process for 2-chlorosulfinylazetidin-4-ones | ELI LILLY AND COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | AHR 3234/4885TP53 857/4885HAO1 3305/4885 |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | AHR 1618/4885TP53 2501/4885HAO1 3264/4885 |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | AHR 1769/4885TP53 2960/4885HAO1 3707/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | AHR 437/4885TP53 835/4885HAO1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.